^
Association details:
| Biomarker: | ER Y537S |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | CB-103 (Notch inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer
Published date:
08/12/2023
Excerpt:
We evaluated the anti-tumor activity of CB-103 with fulvestrant in ESR1-mutant (Y537S), endocrine-resistant BC xenografts….Combination of CB-103 and fulvestrant significantly reduced tumor volume in an ESR1-mutant, the endocrine-resistant BC model.
DOI:
10.3390/cancers15153957
